Table 2.
Treatment-related adverse events according to monotherapy or combination therapy
| Preferred term | All grades | Grade 1-2 | Grade 3 |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| Fatigue | 13 (26%) | 13 (26%) | 0 |
| UTD1 monotherapy | 2 (4%) | 2 (4%) | 0 |
| Combination therapy | 11 (22%) | 11 (22%) | 0 |
| Diarrhea | 8 (16%) | 8 (16%) | 0 |
| UTD1 monotherapy | 3 (6%) | 3 (6%) | 0 |
| Combination therapy | 5 (10%) | 5 (10%) | 0 |
| Decreased appetite | 6 (12%) | 6 (12%) | 0 |
| UTD1 monotherapy | 0 | 0 | 0 |
| Combination therapy | 6 (12%) | 6 (12%) | 0 |
| Anemia | 21 (42%) | 21 (42%) | 0 |
| UTD1 monotherapy | 0 | 0 | 0 |
| Combination therapy | 21 (42%) | 21 (42%) | 0 |
| Peripheral neurotoxicity | 34 (68%) | 32 (64%) | 2 (4%) |
| UTD1 monotherapy | 3 (6%) | 2 (4%) | 1 (2%) |
| Combination therapy | 31 (62%) | 30 (60%) | 1 (2%) |
| Alopecia | 14 (28%) | 14 (28%) | 0 |
| UTD1 monotherapy | 4 (8%) | 4 (8%) | 0 |
| Combination therapy | 10 (20%) | 10 (20%) | 0 |
| Dizzy | 12 (24%) | 12 (24%) | 0 |
| UTD1 monotherapy | 3 (6%) | 3 (6%) | 0 |
| Combination therapy | 9 (18%) | 9 (18%) | 0 |
| Leukopenia | 7 (14%) | 7 (14%) | 0 |
| UTD1 monotherapy | 0 | 0 | 0 |
| Combination therapy | 7 (14%) | 7 (14%) | 0 |
| ALT increased | 5 (10%) | 5 (10%) | 0 |
| UTD1 monotherapy | 0 | 0 | 0 |
| Combination therapy | 5 (10%) | 5 (10%) | 0 |
UTD1, utidelone.